

The BetMakers Holdings Limited ABN: 21 164 521 395

Phone: 1300 886 503 Fax: (02) 4962 2553 22 Lambton Road Broadmeadow NSW 2292

10 September 2018

Second tranche of shortfall placement completed

The Board of The BetMakers Holdings Limited (ASX:TBH) ("Company") is pleased to announce that the second tranche of the shortfall placement from the Company's recent entitlement offer ("Shortfall Placement") has been completed.

The Company has today allotted 7,762,500 fully paid ordinary shares to raise \$621K (before costs), being the second tranche of the Shortfall Placement.

The second tranche of shares issued under the Shortfall Placement were issued to sophisticated and institutional investors in conjunction with the cleansing prospectus issued on 7 September 2018 pursuant to section 708A(11) of the Corporations Act.

An Appendix 3B is attached.

For further information, please contact:

Charly Duffy
Company Secretary
companysecretary@thebetmakers.com
+ 61 (0) 409 083 780

Jane Morgan
Investor & Media Relations
<u>investors@thebetmakers.com</u>
+61 (0) 405 555 618

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Name of entity

The Betmakers Holdings Limited

ABN

21 164 521 395

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- 1 +Class of +securities issued or to be issued
- 1. Fully paid ordinary shares (Shares)
- 2. Shares that may be issued
- Number of *securities issued or to be issued (if known) or maximum number which may be issued
- 7,762,500 Shares issued under the shortfall facility of the pro-rata nonrenounceable entitlement offer (Placement)
- 2. 1,250 Shares that may be issued
- Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)
- 1. Issue of fully paid ordinary shares under the Placement
- 2. Proposed issue of fully paid ordinary shares

04/03/2013 Appendix 3B Page 1

⁺ See chapter 19 for defined terms.

4 Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?

If the additional *securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment
- 5 Issue price or consideration

Yes, the Shares will rank equally in all respects with the existing fully paid ordinary shares on issue.

- 1. \$0.08 per Share
- Shares offered at \$0.08 per Share pursuant to a prospectus dated 7 September 2018
- 6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)
- The funds raised from the Placement will be used to contribute towards the following:
 - The Company is looking to increase its product suite for the wholesale Data & Analytics division of the business and will use funds to continue development and monetisation of these products.
 - The Company has entered into binding agreements with both Dynamic Odds and Global Betting Services and will use funds raised to complete these transactions and to make the initial payments to acquire control of the entities (should the conditions precedent to each transaction be satisfied or waived).
- 2. Offer of Shares pursuant to a prospectus dated 7 September 2018, prepared primarily for the purposes of s708A(11) of the Corporations Act to remove secondary trading restrictions on the Shares issued pursuant to the Placement.

Appendix 3B Page 2 30/06/2016

⁺ See chapter 19 for defined terms.

6a	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?	Yes
	If Yes, complete sections 6b – 6h <i>in relation to the *securities the subject of this Appendix 3B</i> , and comply with section 6i	
6b	The date the security holder resolution under rule 7.1A was passed	22 November 2017
6c	Number of *securities issued without security holder approval under rule 7.1	1,250
6d	Number of *securities issued with security holder approval under rule 7.1A	N/A
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A
6f	Number of *securities issued under an exception in rule 7.2	7,762,500
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A
6h	If +securities were issued under	N/A
OH	rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	IV/A
e:	Calculate the outiful a secreticing	7.4. 22.044.550
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	7.1: 33,614,558 7.1A: 22,410,539

o4/o3/2013 Appendix 3B Page 3

⁺ See chapter 19 for defined terms.

7 +Issue dates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

	10 September 2018
y	
Э	
)	
е	

8 Number and *class of all *securities quoted on ASX (including the *securities in section 2 if applicable)

Number	+Class
224,106,640*	Fully paid ordinary shares
	*including 1,250 Shares offered pursuant to a prospectus dated 7 September 2018

9 Number and *class of all *securities not quoted on ASX (*including* the *securities in section 2 if applicable)

Number	⁺ Class
9,750,000	Unlisted Options (exercisable at \$0.20; expiring 12/11/18)
16,667,000	Unlisted Options (exercisable at \$0.25; expiring 12/11/20; subject to various performance hurdles)
2,000,000	Unlisted Options (exercisable at \$0.25; expiring 21/3/19; subject to various performance hurdles)
1,000,000	Unlisted Options (exercisable at \$0.30; expiring 30/11/19; subject to vesting conditions)
3,000,000	Unlisted Options (exercisable at \$0.25; expiring 30/11/19; subject to vesting conditions)
2,954,681	Unlisted Options (exercisable at \$0.30; expiring 31/10/20; subject to vesting conditions)

10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

N/A

Appendix 3B Page 4 30/06/2016

⁺ See chapter 19 for defined terms.

Part 2 - Pro rata issue

11	Is security holder approval required?	N/A
4.0		F
12	Is the issue renounceable or non-renounceable?	N/A
13	Ratio in which the *securities will be offered	N/A
14	*Class of *securities to which the offer relates	N/A
15	[†] Record date to determine entitlements	N/A
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
	endlements:	
17	Policy for deciding entitlements in relation to fractions	N/A
18	Names of countries in which the entity has security holders who will not be sent new offer documents	N/A
	Note: Security holders must be told how their	
	entitlements are to be dealt with.	
	Cross reference: rule 7.7.	
19	Closing date for receipt of	
	acceptances or renunciations	N/A
20		N/A N/A
20	acceptances or renunciations	
20	acceptances or renunciations	
20	acceptances or renunciations	
	acceptances or renunciations Names of any underwriters Amount of any underwriting fee	N/A
	acceptances or renunciations Names of any underwriters Amount of any underwriting fee	N/A
21	acceptances or renunciations Names of any underwriters Amount of any underwriting fee or commission Names of any brokers to the	N/A N/A
21	acceptances or renunciations Names of any underwriters Amount of any underwriting fee or commission Names of any brokers to the	N/A N/A
21	acceptances or renunciations Names of any underwriters Amount of any underwriting fee or commission Names of any brokers to the	N/A N/A

04/03/2013 Appendix 3B Page 5

⁺ See chapter 19 for defined terms.

Appendix 3B New issue announcement

24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements in full through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A
32	How do security holders dispose of their entitlements (except by sale through a broker)?	N/A
33	*Issue date	N/A

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

- Type of *securities (tick one)
- (a) Securities described in Part 1

Appendix 3B Page 6 30/06/2016

⁺ See chapter 19 for defined terms.

(b)		All other *securities Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities			
Entiti	es th	at have ticked box 34(a)			
Additio	Additional securities forming a new class of securities				
	Tick to indicate you are providing the information or documents				
35		If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders			
36		If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over			
37		A copy of any trust deed for the additional *securities			
Entiti	es th	at have ticked box 34(b)			
38		umber of *securities for which juotation is sought N/A			
39		ass of *securities for which N/A tation is sought			

o4/o3/2013 Appendix 3B Page 7

⁺ See chapter 19 for defined terms.

40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	N/A	
	If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now	N/A	
	Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another *security, clearly identify that other *security)		
		Number	⁺ Class
42	Number and *class of all *securities quoted on ASX (including the *securities in clause 38)	N/A	N/A

Appendix 3B Page 8 30/06/2016

⁺ See chapter 19 for defined terms.

Quotation agreement

- [†]Quotation of our additional [†]securities is in ASX's absolute discretion. ASX may quote the [†]securities on any conditions it decides.
- We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the
 †securities to be quoted under section 1019B of the Corporations Act at the time that we request that the †securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:		Date: 10 September 2018
	(Company Secretary)	

Print name: Charly Duffy

== == == ==

o9/05/2013 Appendix 3B Page 9

⁺ See chapter 19 for defined terms.

Appendix 3B - Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid *ordinary securities on issue 12 months before the *issue date or date of agreement to issue	164,447,158	
Add the following: Number of fully paid *ordinary securities issued in that 12 month	250,000 Ordinary Shares issued on 28 December 2017 upon the exercise of that number of unlisted options	
 period under an exception in rule 7.2 Number of fully paid [†]ordinary securities issued in that 12 month 	3,508,771 Ordinary Shares issued on 26 February 2018 approved at the meeting held on 18 June 2018	
 period with shareholder approval Number of partly paid †ordinary securities that became fully paid in that 12 month period 	12,961,897 Ordinary Shares issued on 31 July 2018 under the institutional component of the pro-rata non- renounceable entitlement offer	
Note: Include only ordinary securities here – other classes of equity securities cannot be added	5,437,564 Ordinary Shares issued on 21 August 2018 under the retail component of the pro-rata non-renounceable entitlement offer	
 Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of 	29,737,500 Ordinary Shares issued on 3 September 2018 under the first tranche of the shortfall facility of the pro-rata non- renounceable entitlement offer	
securities on different dates as separate line items	7,762,500 Ordinary Shares issued on 10 September 2018 under the second tranche of the shortfall facility of the pro-rata non- renounceable entitlement offer	
Subtract the number of fully paid †ordinary securities cancelled during that 12 month period	0	
"A"	224,105,390	

Appendix 3B Page 10 30/06/2016

⁺ See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"		
"B"	0.15 [Note: this value cannot be changed]	
Multiply "A" by 0.15	33,615,808	
Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used		
Insert number of *equity securities issued or agreed to be issued in that 12 month period not counting those issued:	1,250 Ordinary Shares offered pursuant to a prospectus dated 7 September 2018.	
Under an exception in rule 7.2		
Under rule 7.1A		
With security holder approval under rule 7.1 or rule 7.4		
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 		
"C"	1,250	
Step 4: Subtract "C" from ["A" x " placement capacity under rule 7.1	<u>-</u>	
"A" x 0.15	33,615,808	
Note: number must be same as shown in Step 2		
Subtract "C" Note: number must be same as shown in	1,250	
Step 3		
Total ["A" x 0.15] – "C"	33,614,558	

09/05/2013 Appendix 3B Page 11

⁺ See chapter 19 for defined terms.

Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A" Note: number must be same as shown in	224,105,390	
Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
Multiply "A" by 0.10	22,410,539	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
Insert number of *equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	0	
 Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as 		
separate line items		

Appendix 3B Page 12 30/06/2016

⁺ See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10 Note: number must be same as shown in Step 2	22,410,539
Subtract "E" Note: number must be same as shown in Step 3	0
<i>Total</i> ["A" x 0.10] – "E"	22,410,539 Note: this is the remaining placement capacity under rule 7.1A

09/05/2013 Appendix 3B Page 13

⁺ See chapter 19 for defined terms.